Xueliang Liu
Xuelianghc@163.com
Education and Professional Experience
Shanghai Jiao Tong University | 2024–Present
Associate Researcher
Affiliations: School of Medicine, Renji Hospital, Institute of Molecular Medicine (Punan Branch)
Shanghai Jiao Tong University | 2021–2024
Postdoctoral Fellow
Affiliations: School of Medicine, Renji Hospital, Institute of Molecular Medicine
Advisor: Prof. Yu Yang
Shanghai Jiao Tong University | 2016–2021
Ph.D. in Biomedical Sciences
Department: Pharmacology and Chemical Biology, Basic Medical Sciences
Advisor: Prof. Chao Fang
Shandong University | 2012–2016
B.S. in Pharmaceutical Sciences
Key Laboratory of Natural Products Chemical Biology (Ministry of Education)
Research Mentor: Prof. Wenfang Xu
Research Focus
1. Engineering structurally adaptive metal-DNA nanoplatforms to overcome biological barriers (e.g., tumor stroma, immune evasion) as novel strategies for combined chemotherapy, phototherapy, and immunotherapy.
2. Designing nucleic acid/nanomaterial hybrids that dynamically sense and modulate the tumor microenvironment (TME) for efficient and precise tumor therapy.
Representative Publications：
10. Xueliang Liu#, Fan Li#, Ziliang Dong, Chao Gu, Dongsheng Mao , Jingqi Chen1, Lei Luo, Yuting Huang, Jie Xiao*, Zhanchun Li*, Zhuang Liu*, Yu Yang*. Metal-polyDNA nanoparticles reconstruct osteoporotic microenvironment for enhanced osteoporosis treatment, Science Advances, 2023, 9(31), eadf3329. Highlighted by Nat. Rev. Rheumatol. 2023,19, 606. (IF=13.6)
9. Xueliang Liu#, Binghua Chen#, Jingqi Chen#, Xuan Wang, Xinfeng Dai, Yuqing Li, Huayuan Zhou, Lianming Wu*, Zhuang Liu*, Yu Yang*.A Cardiac-Targeted Nanozyme Interrupts the Inflammation-Free Radical Cycle in Myocardial Infarction, Advanced Materials, 2024, 36(2): 2308477. (IF=29.4)
8. Xue-Liang Liu, Xiao Dong, Si-Cong Yang, Xing Lai, Hai-Jun Liu, Yuhao Gao, Hai-Yi Feng, Mao-Hua Zhu, Yihang Yuan, Qin Lu, Jonathan F. Lovell, Hong-Zhuan Chen,* Chao Fang*. Biomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy. Advanced Science, 2021, 8(8): 2003679. (IF=17.521)
7. Yuqing Li#, Xueliang Liu#, Lu Yu, Xin Huang, Xuan Wang, Da Han*, Yu Yang*, and Zhuang Liu*. Covalent LYTAC Enabled by DNA Aptamers for Immune Checkpoint Degradation Therapy, Journal of the American Chemical Society, 2023,145, 45, 24506–24521. (IF=15.0)
6. Yuting Huang#, Xueliang Liu#, Jiawei Zhu#, Zhejie Chen, Lu Yu, Xin Huang, Chuhuang Dong, Jiabei Li, Huayuan Zhou, Yu Yang*, Weihong Tan1. Enzyme core spherical nucleic acid that enables enhanced cuproptosis and anti-tumor immune response through alleviating tumor hypoxia, Journal of the American Chemical Society, 2024. Just Accepted. (IF=15.0)
5. Chao Gu#, Xueliang Liu#, Lei Luo, Jingqi Chen, Xiao Zhou, Ganghui Chen, Xin Huang, Lu Yu, Qian Chen, Yu Yang*, and Yang Yang*. Metal-DNA Nanocomplexes Enhance Chemo-dynamic Therapy by Inhibiting Autophagy-Mediated Resistance, Angewandte Chemie International Edition, 2023, 62(50): e202307020. (IF=16.6)
4. Ziyi Gu#, Xueliang Liu#, Zhen Qi, Zhou Fang, Yiting Jiang, Yuting Huang, Yongyi Wang* Lianming Wu*, Yu Yang*. A antioxidant nanozyme for targeted cardiac fibrosis therapy post myocardial infarction, Chemical Engineering Journal, 2024. In minor revision. (IF=15.1)
3. Guowang Cheng#, Xueliang Liu#, Yujing Liu, Yao Liu, Rui Ma, Jingshan Luo, Xinyi Zhou, Zhenfeng Wu*, Zhuang Liu, Tongkai Chen*, Yu Yang*. Ultrasmall Coordination Polymers for Alleviating ROS-Mediated Inflammatory and Realizing Neuroprotection against Parkinson’s Disease. Research, 2022, 9781323. (IF=11.0)
2. Jian Wang#, Jiayi Wang#, Huayuan Zhou, Rui Ma, Zhou Fang, Jiawei Zhu, Zhejie Chen, Xinfeng Dai, Dali Wei, Jiabei Li, Yiting Jiang, Qian Xia*, Xueliang Liu*, Yu Yang*. Universal Antibacterial and Anti-inflammatory Treatment using Chitosan-Prussian Blue Nanozyme, EngMedicine, 2024.
1. Jiayi Wang#, Jiahua Pan#, Yijun Tang, Jingqi Chen, Xiaochen Fei, Wei Xue* and Xueliang Liu*. Advances of hafnium based nanomaterials for cancer theranostics. Frontiers in Chemistry, 2023, 11: 1283924. (IF=5.5)